title: Effect of oral factor Xa inhibitor and low-molecular-weight heparin on surgical complications following total hip arthroplasty.
abstract: This prospective study was conducted to report the effect of oral factor Xa inhibitor and low-molecular-weight heparin (LMWH) on surgical complications following total hip arthroplasty (THA). The patients with an age < 60 years were randomly assigned to three groups (rivaroxaban, enoxaparin, and placebo) and the patients with an age ≥ 60 years were assigned to two groups (rivaroxaban and enoxaparin). All drug regimens started at 12 hours postoperatively and continued for two weeks after surgery. Primary measure outcome was major surgical wound complications defined as haematoma requiring any intervention, superficial wound infection, deep periprosthetic infection, and increased wound bleeding. Secondary measured outcome included minor surgical complications (swelling, drainage, erythema, and oozing), organ bleeding, and venous thromboembolic (VTE) events. A total of 184 patients aged < 60 years and 167 patients aged ≥ 60 years were included as the analysis population per group. Up to 14 days after surgery, the overall incidence of major surgical complications associated with thromboprophylaxis was 6.5 % (58/886). There were no significant differences in the rate of major surgical complications among all the three groups of the patients aged < 60 years and between two groups of the patients aged ≥ 60 years. For the patients aged < 60 years, wound oozing continued significantly longer in the pharmacological group than in the placebo group, but wound infection did not occur in any case. The VTE events were similar in all the groups.
authors.forename: Sang-Min
authors.initials: SM
authors.lastname: Kim
authors.forename: Young-Wan
authors.initials: YW
authors.lastname: Moon
authors.forename: Seung-Jae
authors.initials: SJ
authors.lastname: Lim
authors.forename: Dong-Wook
authors.initials: DW
authors.lastname: Kim
authors.affiliation: Youn-Soo Park, Department of Orthopedic Surgery, Samsung Medical Center, Sungkyunkwan University School of Medicine, 50 Irwon-dong, Gangnam-gu, Seoul, 135-710, South Korea, Tel.: +82 2 3410 3509, Fax: +82 2 3410 0061, E-mail: ysp3504@skku.edu.
authors.forename: Youn-Soo
authors.initials: YS
authors.lastname: Park
mesh_terms: D000368:Aged; D000925:Anticoagulants / Q000627:therapeutic use*; D019644:Arthroplasty, Replacement, Hip; D017984:Enoxaparin / Q000008:administration & dosage*; D065427:Factor Xa Inhibitors / Q000627:therapeutic use*; D005260:Female; D006470:Hemorrhage / Q000139:chemically induced / Q000517:prevention & control; D006495:Heparin, Low-Molecular-Weight / Q000627:therapeutic use*; D006801:Humans; D008297:Male; D008875:Middle Aged; D010919:Placebos; D011183:Postoperative Complications; D011184:Postoperative Period; D011446:Prospective Studies; D000069552:Rivaroxaban / Q000008:administration & dosage*; D016896:Treatment Outcome; D054556:Venous Thromboembolism / Q000150:complications / Q000209:etiology / Q000517:prevention & control*; D014945:Wound Healing
chemical_list: D000925:Anticoagulants; D017984:Enoxaparin; D065427:Factor Xa Inhibitors; D006495:Heparin, Low-Molecular-Weight; D010919:Placebos; D000069552:Rivaroxaban
keywords: Oral direct factor Xa inhibitor; low-molecular-weight heparin; surgical complications; thromboprophylaxis; total hip arthroplasty